T cell-depleted stem-cell transplantation for adults with hematologic malignancies: Sustained engraftment of HLA-matched related donor grafts without the use of antithymocyte globulin

Blood

Volumn 110, Issue 13, 2007, Pages 4552-4559

  Jakubowski, Ann A ^a,b   Small, Trudy N ^a   Young, James W ^a   Kernan, Nancy A ^a   Castro Malaspina, Hugo ^a   Hsu, Katherine C ^a   Perales, Miguel Angel ^a   Collins, Nancy ^a   Cisek, Christine ^a   Chiu, Michelle ^a   Van Den Brink, Marcel R M ^a   O'Reilly, Richard J ^a   Papadopoulos, Esperanza B ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUDARABINE; THIOTEPA; THYMOCYTE ANTIBODY; HLA ANTIGEN; LYMPHOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ARTICLE; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DISEASE FREE SURVIVAL; FEMALE; HEMATOLOGIC MALIGNANCY; HLA MATCHING; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OPPORTUNISTIC INFECTION; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; RISK ASSESSMENT; STEM CELL TRANSPLANTATION; T CELL DEPLETION; WHOLE BODY RADIATION; ALLOTRANSPLANTATION; BLOOD DISEASE; CLINICAL TRIAL; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE DEPLETION; METHODOLOGY; MIDDLE AGED;

ADULT; ANTILYMPHOCYTE SERUM; DISEASE-FREE SURVIVAL; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA ANTIGENS; HUMANS; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 39649110913     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-06-093880     Document Type: Article

References (39)

1. Young JW, Papadopoulos EB, Cunningham I, et al. T-cell depleted allogeneic bone marrow transplantation in adults with acute nonlymphocytic leukemia in first remission. Blood. 1992;79:3380-3387.
2. Papadopoulos EB, Carabasi MH, Castro-Malaspina H, et al. T-cell depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host-disease. Blood. 1998;91:1083-1090.
3. Small TN, Avigan D, Dupont B, et al. Immune reconstitution following T-cell depleted bone marrow transplantation: effect of age and posttransplant graft rejection prophylaxis. Biol Blood Marrow Transplant. 1997;3:65-75.
4. Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100:4325-4336.
5. Shank B, Chu FCH, Dinsmore R, et al. Hyperfractionated total body irradiation for bone marrow transplantation: results in seventy leukemia patients with allogeneic transplant. Int J Radiat Oncol Biol Phys. 1983;9:1607-1611.
6. Collins NH, Fernandez JM, Bleau S, et al. Comparison of bone marrow and G-CSF mobilized peripheral blood progenitor cells from single normal donors before and after T cell depletion. Cytotherapy. 1999;1:223. Abstract.
7. Collins NH, Bleau SA, Kernan NA, O'Reilly RJ. T cell depletion of bone marrow by treatment with soybean agglutinin and sheep red blood cell rosetting. In: Areman HJ, Deeg HJ, Sacher RA, eds. Bone Marrow and Stem Cell Processing: A Manual of Current Techniques. Philadelphia, PA: F.A. Davis; 1991:171-180.
8. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation. 1974;18:295-304.
9. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-vs-host syndrome in man: a long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69:204-217.
10. Niesters HG, van Esser J, Fries E, Wolthers KC, Cornelissen J, Osterhaus AD. Development of a real-time quantitative assay for detection of Epstein-Barr virus. J Clin Microbiol. 2000;38:712-715.
11. Small TN, Papadopoulos EB, Boulad F, et al. Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions. Blood. 1999;93:467-480.
12. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. Wiley: New York, NY; 1980.
13. Kernan NA, Collins NH, Juliano L, Catagena T, DuPont B, O'Reilly RJ. Clonable T lymphocytes in T-cell depleted bone marrow transplants correlate with development of graft vs. host disease. Blood. 1986;68:770-773.
14. Kernan NA, Bordignon C, Heller G, et al. Graft failure after T-cell-depleted human leukocyte antigen identical marrow transplants for leukemia: I, analysis of risk factors and results of secondary transplants. Blood. 1989;74:2227-2236.
15. Bordignon C, Keever CA, Small TN, et al. Graft failure after T-cell-depleted human leukocyte antigen identical marrow transplants for leukemia: II, in vitro analyses of host effector mechanisms. Blood. 1989;74:2237-2243.
16. + cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation. Leukemia. 2005;19:822-888.
17. Reisner Y, Martelli MF. Bone marrow transplantation across HLA barriers by increasing the number of transplanted cells. Immunol Today. 1995;16:437-440.
18. Zaucha JM, Gooley T, Bensinger WI, et al. CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation. Blood. 2001;98:3221-3227.
19. Yakoub-Agha I, Mesnil F, Kuentz M, et al. Allogeneic marrow stem-cell trnsplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy. J Clin Oncol. 2006;24:5695-5702.
20. Ditschkowski M, Elmaagacli AH, Trenschel R, Steckel NK, Koldehoff M, Beelen DW. Myeloablative allogeneic hematopoietic stem cell transplantation in elderly patients. Clin Transplant. 2006;20:127-131.
21. Marks DI, Forman SJ, Blume KG, et al. A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first and second complete remission. Biol Blood Marrow Transplant. 2006;12:438-453.
22. Przepiorka D, Smith TL, Folloder J, Khouri I, et al. Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood. 1999;94:1465-1470.
23. Stem Cell Trialists' Collaborative Group. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol. 2005;23:5074-5087.
24. Deeg HJ, Storer BE, Boeckh M, et al. Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. Biol Blood Marrow Transplant. 2006;12:573-584.
25. Pavletic S, Smith L, Bishop M, et al. Prognostic factors of chronic graft-versus-host disease after allogeneic blood stem-cell transplantation. Am J Hematol. 2005;78:265-274.
26. Wallen H, Gooley TA, Deeg HJ, et al. Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older. J Clin Oncol. 2005;23:3439-3446.
27. van Besien K, Loberiza FB, Bajorunaite R Jr, et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood. 2003;102:3521-3529.
28. + cells with T-cell add-back compared with unmanipulated bone marrow or peripheral blood stem cells from HLA-identical sibling donors in patients with first chronic phase chronic myeloid leukemia. Blood. 2003;101:446-453.
29. Hunault M, Harousseau J-L, Delain M. Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial. Blood. 2004;104:3028-3037.
30. Law LY, Hornig SJ, Wong RM, et al. High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2006;12:703-711.
31. Schmitz N, Beksac M, Hasenclever D, et al. Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. Blood. 2002;100:761-767.
32. O'Reilly RJ, Small TN, Papodopoulos E, Lucas K, Lacerda J, Koulova L. Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts. Immunol Rev. 1997;195-216.
33. Jaffe D, Jakubowski A, Sepkowitz K, et al. Prevention of peritransplantation viridans Streptococcal bacteremia with early vancomycin administration: a single center observational cohort. Clin Infect Dis. 2004;39:1625-1632.
34. Giralt S, Thall PF, Khouri I, et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood. 2001;97:631-637.
35. Sayer HG, Kroger M, Beyer J, et al. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor. Bone Marrow Transplant. 2003;31:1089-1095.
36. Burroughs L, Mielcarek M, Leisenring W, et al. Extending postgrafting cyclosporine decreases the risk of severe graft-versus-host disease after nonmyeloablative hematopoietic cell transplantation. Transplantation. 2006;81:818-825.
37. Baron F, Maris MB, Sandmaier BM, et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol. 2005;23:1993-2003.
38. Ho AYL, Pagliuca A, Kenyon M, et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. Blood. 2004;104:1616-1623.
39. Martino R, Perez-Simon JA, Moreno E, et al., Reduced-intensity conditioning allogeneic blood stem cell transplantation with fludarabine and oral busulfan with or without pharmacokinetically targeted busulfan dosing in patients with myeloid leukemia ineligible for conventional conditioning. Biol Blood Marrow Transplant. 2005;11:437-447.